NZ507764A - Using Ngali Nut Oil to Treat/Relieve the Manifestations of Arthiritis and Other Similar Conditions - Google Patents
Using Ngali Nut Oil to Treat/Relieve the Manifestations of Arthiritis and Other Similar ConditionsInfo
- Publication number
- NZ507764A NZ507764A NZ507764A NZ50776499A NZ507764A NZ 507764 A NZ507764 A NZ 507764A NZ 507764 A NZ507764 A NZ 507764A NZ 50776499 A NZ50776499 A NZ 50776499A NZ 507764 A NZ507764 A NZ 507764A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nut oil
- manifestations
- ngali nut
- arthritis
- ngali
- Prior art date
Links
- 235000019488 nut oil Nutrition 0.000 title claims abstract description 43
- 239000010466 nut oil Substances 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 206010003246 arthritis Diseases 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 239000006071 cream Substances 0.000 claims abstract description 13
- 238000011200 topical administration Methods 0.000 claims abstract description 4
- 208000002193 Pain Diseases 0.000 description 25
- 230000002917 arthritic effect Effects 0.000 description 25
- 230000036407 pain Effects 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 13
- 210000001503 joint Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 201000008482 osteoarthritis Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 210000004247 hand Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 206010042674 Swelling Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000003811 finger Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 241000644798 Canarium <sea snail> Species 0.000 description 2
- 241000857888 Canarium harveyi Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 240000005209 Canarium indicum Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- OJLOPKGSLYJEMD-LNQMSSPSSA-N Cyotec Chemical compound CCCCC(C)(O)CC=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-LNQMSSPSSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940097776 arthrotec Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001811 joint immobility Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Lubricants (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP3796A AUPP379698A0 (en) | 1998-06-01 | 1998-06-01 | Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions |
| PCT/AU1999/000426 WO1999062528A1 (en) | 1998-06-01 | 1999-06-01 | Treatment of arthritis and other similar conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ507764A true NZ507764A (en) | 2003-07-25 |
Family
ID=3808043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ507764A NZ507764A (en) | 1998-06-01 | 1999-06-01 | Using Ngali Nut Oil to Treat/Relieve the Manifestations of Arthiritis and Other Similar Conditions |
| NZ525536A NZ525536A (en) | 1998-06-01 | 2002-02-26 | Treatment of arthritis and other similar conditions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ525536A NZ525536A (en) | 1998-06-01 | 2002-02-26 | Treatment of arthritis and other similar conditions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6395313B1 (ref) |
| EP (1) | EP1083914B1 (ref) |
| JP (1) | JP4583599B2 (ref) |
| CN (1) | CN1251707C (ref) |
| AT (1) | ATE369143T1 (ref) |
| AU (2) | AUPP379698A0 (ref) |
| CA (1) | CA2330659C (ref) |
| DE (1) | DE69936779T2 (ref) |
| ID (1) | ID27052A (ref) |
| IL (1) | IL139303A0 (ref) |
| NZ (2) | NZ507764A (ref) |
| WO (1) | WO1999062528A1 (ref) |
| ZA (1) | ZA200006406B (ref) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053718A1 (en) * | 2003-12-05 | 2005-06-16 | Naturaleaf, Inc. | Methods and compositions for treating inflammatory and dermatological conditions |
| US20060068004A1 (en) * | 2004-09-28 | 2006-03-30 | Aum Nutrapharm Inc. | Buccal delivery of sea cucumber tablets |
| US7794413B2 (en) * | 2005-04-19 | 2010-09-14 | Ev3, Inc. | Libraries and data structures of materials removed by debulking catheters |
| US20070048386A1 (en) * | 2005-08-30 | 2007-03-01 | Mallozzi Ottavio Sr | Medicament for treating inflammatory and non-inflammatory arthritis |
| WO2011122927A1 (en) * | 2010-03-31 | 2011-10-06 | Universiti Putra Malaysia | A vegetable oil and/or fats |
| WO2015099521A2 (en) | 2013-12-24 | 2015-07-02 | Biotropics Malaysia Bhd | Fruit extracts and extract formulations of canarium odontophyllum as actives and related invention embodiments |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2034888B1 (es) * | 1991-07-11 | 1994-02-16 | Madaus Cerafarm Lab | Procedimiento de obtencion de la fraccion acida total de los extractos lipidicos de los frutos del sabal serrulata. |
| JPH09187248A (ja) * | 1995-11-06 | 1997-07-22 | Nippon Oil & Fats Co Ltd | 抗アレルギー食品 |
-
1998
- 1998-06-01 AU AUPP3796A patent/AUPP379698A0/en not_active Abandoned
-
1999
- 1999-06-01 NZ NZ507764A patent/NZ507764A/en not_active IP Right Cessation
- 1999-06-01 US US09/701,503 patent/US6395313B1/en not_active Expired - Fee Related
- 1999-06-01 JP JP2000551784A patent/JP4583599B2/ja not_active Expired - Fee Related
- 1999-06-01 DE DE69936779T patent/DE69936779T2/de not_active Expired - Lifetime
- 1999-06-01 AT AT99955218T patent/ATE369143T1/de not_active IP Right Cessation
- 1999-06-01 IL IL13930399A patent/IL139303A0/xx unknown
- 1999-06-01 AU AU42491/99A patent/AU746083C/en not_active Ceased
- 1999-06-01 EP EP99955218A patent/EP1083914B1/en not_active Expired - Lifetime
- 1999-06-01 CA CA2330659A patent/CA2330659C/en not_active Expired - Fee Related
- 1999-06-01 ID IDW20002494A patent/ID27052A/id unknown
- 1999-06-01 WO PCT/AU1999/000426 patent/WO1999062528A1/en not_active Ceased
- 1999-06-01 CN CNB998068446A patent/CN1251707C/zh not_active Expired - Fee Related
-
2000
- 2000-11-08 ZA ZA200006406A patent/ZA200006406B/en unknown
-
2002
- 2002-02-26 NZ NZ525536A patent/NZ525536A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69936779D1 (de) | 2007-09-20 |
| ZA200006406B (en) | 2002-05-08 |
| IL139303A0 (en) | 2001-11-25 |
| EP1083914A4 (en) | 2002-09-18 |
| ID27052A (id) | 2001-02-22 |
| WO1999062528A1 (en) | 1999-12-09 |
| NZ525536A (en) | 2004-12-24 |
| JP2003523920A (ja) | 2003-08-12 |
| AU746083C (en) | 2002-12-05 |
| EP1083914A1 (en) | 2001-03-21 |
| CA2330659A1 (en) | 1999-12-09 |
| AU4249199A (en) | 1999-12-20 |
| US6395313B1 (en) | 2002-05-28 |
| JP4583599B2 (ja) | 2010-11-17 |
| EP1083914B1 (en) | 2007-08-08 |
| ATE369143T1 (de) | 2007-08-15 |
| AU746083B2 (en) | 2002-04-11 |
| CA2330659C (en) | 2010-11-16 |
| CN1251707C (zh) | 2006-04-19 |
| DE69936779T2 (de) | 2008-07-31 |
| AUPP379698A0 (en) | 1998-06-25 |
| CN1303297A (zh) | 2001-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5854291A (en) | Pain reliever and method of use | |
| US6528076B2 (en) | Topical compositions and methods for treating pain | |
| US7923040B2 (en) | Homeopathic formulations useful for treating pain and/or inflammation | |
| US5856361A (en) | Pain reliever and method of use | |
| Akhoondinasab et al. | Assessing effect of three herbal medicines in second and third degree burns in rats and comparison with silver sulfadiazine ointment | |
| US20130052271A1 (en) | Compositions and Methods for Treating Pain | |
| US5874094A (en) | Cream formulation for topical application | |
| JP2000143507A (ja) | カプサイシン含有外用剤 | |
| WO2017037534A1 (en) | Topical compositions for treatment of psoriasis | |
| CN104147533B (zh) | 一种活血化瘀止痛乳膏及其制备方法 | |
| AU746083B2 (en) | Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions | |
| WO2019241409A1 (en) | Topical composition for pain relief | |
| EP1408999A1 (en) | Compositions addressing inflammation and/or degenerative disorders | |
| USRE36606E (en) | Synergistic pharmaceutical compositions | |
| JPH06199688A (ja) | 面皰治療剤組成物 | |
| AU764101B2 (en) | Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions | |
| US20080145461A1 (en) | Formulation and method of making a topical pain relief composition | |
| Prabhu et al. | Saraswatarishta reverses neuronal injury in brain tissues of scopolamine-induced rat model | |
| MXPA00011408A (es) | Tratamiento de artritis y otras condiciones similares | |
| Serrao et al. | A case of myokymia‐cramp syndrome successfully treated with gabapentin | |
| KR102926625B1 (ko) | 지방분해용 주사제 조성물 | |
| JPS5984826A (ja) | 動物の育毛促進方法 | |
| EP1516631A1 (fr) | Onguent, pour le corps à effets décongestionnant et faire disparaitre progressivement les douleurs musculaires, foulures, entorses, déboitements, courbatures et apaiser les douleurs articulaires et rhumatismales | |
| WO2023170714A1 (en) | A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases | |
| CN110755508B (zh) | 一种消肿止痒中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |